XOMA benefits from a structurally high-margin business model built around royalties and milestones, which need relatively little direct cost to generate revenue. It has assembled a broad, diversified portfolio of royalty interests across many therapeutic areas and partners, reducing dependence on any one product. Historically, the company maintained strong liquidity and has demonstrated the ability to raise capital through both debt and equity to fund acquisitions and support operations. Its niche focus on earlier-stage, smaller royalty deals and its experienced team provide a differentiated position in the healthcare financing landscape.

The main concerns center on financial sustainability and execution risk. Profitability has deteriorated from solid profits to sustained losses, and operating cash flow and free cash flow are now consistently negative. The balance sheet has become more leveraged, with a clear move from net cash to net debt and declining liquidity ratios. Royalty revenue and milestones are inherently volatile, and many underlying programs may fail or underperform, especially given the emphasis on earlier-stage assets. Continued dividends and investment activity, against a backdrop of negative free cash flow, further increase the pressure on the balance sheet and the need for either improved operating performance or continued access to external financing.

Looking ahead, XOMA’s trajectory will largely depend on the maturation of its royalty portfolio and its ability to control costs while managing leverage. A series of upcoming clinical and regulatory events over the next few years could materially improve recurring royalty income if outcomes are favorable and commercial uptake is strong. At the same time, negative cash flows and rising debt levels mean that the company has less room for prolonged disappointment. Overall, the story is one of a differentiated, potentially high-upside business model that is currently in a cash-consuming, loss-making phase, where future results will be driven by partner success, disciplined capital allocation, and tighter cost management.